August 15, 2019

  • Innovative MiSight® 1 day contact lenses1 continue to slow myopia (short-sightedness) progression and axial elongation among children
  • Children who began wearing MiSight® 1 day contact lenses later in the study progress at the same rate after switching as those who commenced treatment three years earlier
  • Outcomes illustrate excellent vision and clinical performance


Southampton, United Kingdom, 15 August 2019 — Five-year data from the world’s longest-running clinical trial involving children wearing contact lenses is offering new myopia management insights for eye care professionals. CooperVision’s latest report from its landmark MiSight® 1 day study1,2 comes as optometrists, ophthalmologists and public health authorities are facing the growing worldwide severity and prevalence of progressive childhood myopia.


Myopia—also known as short-sightedness—is projected to affect the vision and increase risks to ocular health of approximately five billion people by 2050, more than doubling today’s numbers3. CooperVision researchers were among the first to seek well-tolerated and effective methods to limit myopia progression. From those efforts came MiSight® 1 day, the first soft contact lens specifically designed to slow myopia progression in children.


Part one of the study quantified three-year effectiveness of the innovative MiSight® 1 day lens versus an equivalent single vision 1-day lens in slowing the rate of progression of juvenile-onset myopia. The peer-reviewed “A 3-Year Randomized Clinical Trial of MiSight Lenses for Myopia Control” is now available in pre-publication format from Optometry and Vision Science.4


Part two was initiated at the 36-month mark, when children in the original control group were refit with MiSight® 1 day. They continued to be tracked separately to compare the rate of myopia progression between the two matched populations with different treatment history.


The latest data reveals that:


  • Progression rates among the original control group (after already showing a dramatic reduction in year four following refitting) matched the children who had been wearing MiSight® 1 day for the entire duration of the study in spherical equivalent refractive error (0.17D) and axial length (0.07mm) during year five.


  • Vision performance remained excellent among both groups, with visual acuity of better than 6/6 at every scheduled appointment, with no significant differences across groups or visits.


Furthermore, there were minimal adverse events and changes in anterior eye clinical observations across both groups.


“The mirrored slowed progression across both groups suggests that myopia progression with MiSight® 1 day lenses is more dependent on age of the patient than their baseline myopia or length of time under treatment,” said Paul Chamberlain, Director of Research Programs for CooperVision. “The children more recently entering treatment are progressing at the same rate as those completing their fifth year of MiSight® 1 day wear. This information can help practitioners as they also consider treating slightly older kids than studied in part one of the trial.”


“The data and insights from this multi-year clinical trial are powerful, reinforcing the positive impact of this lens on myopic children,” said Daniel McBride, President of CooperVision. “Our dedication to helping eye care professionals address the myopia epidemic in younger patients is unwavering, demonstrated through research, education and distinctive offerings such as MiSight® 1 day.”


No other prospective randomised controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a 1-day soft contact lens over five years. Physiological changes among 108 myopic children from Singapore, Canada, England, and Portugal were evaluated during the latest reported period.


Presentation of the five-year data and continued research are part of a series of far-reaching initiatives by CooperVision to educate eye care professionals and aligned healthcare practitioners about advances in myopia management, including widespread conference participation, study support, clinical training events and more.


In June, a trio of myopia management visionaries were honoured with the prestigious 2019 British Contact Lens Association (BCLA) Industry Award for their work developing, researching and commercialising MiSight® 1 day. John Phillips, Stuart Cockerill and Paul Chamberlain were selected from a field of finalists who have all made immeasurable contributions to the field.


# # #

1 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand.

2 Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 5-year results (2019 BCLA Clinical Conference & Exhibition).

3 Holden et al, - Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042

4 Chamberlain P, Peixoto-de-Matos Logan N, Ngo C, Jones D, Young G. A 3-Year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optometry and Vision Science. July 19, 2019 - Volume Pre-Publication - Issue – p doi: 10.1097/OPX.0000000000001410.


About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit


About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women’s health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has more than 11,000 employees with products sold in over 100 countries. For more information, please visit


MEDIA CONTACT:    Fiona Healey, Five by Five


         02380 827372